1Y Target$208.80Near-term target
5Y Target$322.42Compound horizon
10Y Target$838.98Long-dated conviction
FCF$391mTTM · 03/26CFCF $391m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+1.2%TTM YoYCRevenue +1.2% — flat, mature phase or headwinds present
D/E1.03C+D/E 1.03 — moderately levered, watch interest coverage
P/S1.9xA-P/S 1.9x — cheap for any tech/growth name
PEG0.12APEG 0.12 — exceptional; paying well under fair value for growth
Why now
Diagnostics & Research · market cap $7.7b. Down 30% from 52-week high of $228.88 — deep drawdown territory. PEG 0.12 — paying under fair value for the growth rate. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $208.80 (implying +30% upside).
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Currently unprofitable (margin -4.6%) — path to GAAP profitability is the core thesis risk. Beta 1.45 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -6% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $208.80 (15-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $322.42 — requires the platform / technology to reach commercial scale. 10 yr $838.98 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.